Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Antibody-drug conjugates" has been added to ResearchAndMarkets.com's offering.
ntibody-drug conjugates (ADCs) are redefining cancer treatment by merging monoclonal antibodies with chemotherapy drugs for precise targeting. This method enhances drug efficacy and minimizes side effects, showcasing promising outcomes across various cancers like breast cancer, lymphoma, and leukemia. Ongoing developments aim to optimize ADCs, making them more effective against cancer cells.
The ADC sector is a dynamic sphere of biopharmaceutical innovation. Major pharmaceutical entities, responsible for 37% of all patents, are spearheading this evolution with a deep pipeline, recent drug approvals, and strategic investments such as mergers and acquisitions. Since 2017, patent filings have surged, with expanding applications in autoimmune and infectious diseases introducing more players to the field. The United States and China lead in this innovative journey, with more than 100 public companies competing fervently.
Key patent contributors are Roche, Seagen (Pfizer), AstraZeneca, and Abbvie, with Daiichi Sankyo, AstraZeneca, and Abbvie boasting robust patent portfolios. In China's burgeoning market, Jiangsu Hengrui, Biocytogen, and GeneQuantum top the list of active companies. The ecosystem comprises over 70 startups, prominently GeneQuantum, Oncomatryx, Glykos, and DAC Biotech, pushing the boundaries of innovation.
The ADC drug landscape is populated by 1,172 drugs, primarily directed at oncology (94%). Methods of administration largely involve intravenous delivery, with Biocytogen Pharmaceuticals and Hangzhou DAC Biotech prominent in preclinical and Phase II drug development. The wealth of drugs in Phase I and II trials signals a maturing pipeline poised for imminent market entry.
There have been 2,847 clinical trials for ADCs, dominated by oncology, specifically targeting Hodgkin Lymphoma. Pfizer and Daiichi Sankyo emerge as leading trial sponsors. Financially, the sector sees robust activity with 809 deals amassing US$227 billion, dominated by the United States in both volume and value. While the market faced a downturn in deals from 2020 to 2022, a rebound in 2023 underscores strategic consolidations and market recalibration.
Key Highlights
- The ADC sector is a high-impact area in pharma, focusing on areas like Oncology and Autoimmune Diseases.
- Established pharma companies like Roche dominate ADC-related patents despite a recent slowdown in new patent filers.
- Merck and Seagen stand out for their significant innovation portfolios in ADCs.
- The drug landscape is marked by the prevalence of innovator drugs, with Biocytogen and Hangzhou Biotech as leaders in development.
- In clinical trials, Immunology is a prominent field, with heavy involvement from Pfizer Inc and Daiichi Sankyo Ltd.
Scope
- Innovation Insights: Presents key trends across various sectors.
- Key Players: Showcases major contributors to advancements in the field.
- Startups: Highlights emerging players in the industry.
- University Involvement: Outlines leading academic institutions contributing to the field.
Key Topics Covered:
1. Innovation Insights
1.1 Innovation radar
1.2 Innovation s-curve
1.3 Innovation deep dive
2. Competitive Insights
2.1 Key innovation leaders - big pharma
2.2 Key innovators - startups and small biotech
3. Market Insights
3.1 Drugs
3.2 Clinical Trials
3.3 Deals
A selection of companies mentioned in this report includes, but is not limited to:
- Biocytogen Pharmaceuticals (Beijing) Co Ltd
- Hangzhou DAC Biotech Co Ltd
- LigaChem Biosciences Inc
- Pfizer Inc
- Genmab AS
- Cidara Therapeutics Inc
- Duality Biologics (Shanghai) Co Ltd
- Shanghai Affinity Biopharmaceutical Co Ltd
- AstraZeneca Plc
- Immunome Inc
- AbTis Co Ltd
- iProgen Biotech Inc
- Suzhou Medilink Therapeutics Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Innovent Biologics Inc
- ADC Therapeutics SA
- AbbVie Inc
- Hangzhou Adcoris Biopharmaceutical Co Ltd
- LaNova Medicines Ltd
- GeneQuantum Healthcare Suzhou Co Ltd
- Alphamab Oncology
- Exelixis Inc
- Merck KGaA
- Mersana Therapeutics Inc
- Zymeworks Inc
- Xiling Lab Co Ltd
- Intocell Inc
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- MabGen Biotech Co Ltd
- SOTIO Biotech AS
- BiOneCure Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Multitude therapeutics Inc
- Iksuda Therapeutics Ltd
- Bio-Thera Solutions Ltd
- Oxford BioTherapeutics Ltd
- Sichuan Biokin Pharmaceutical Co Ltd
- Byondis BV
- Actinium Pharmaceuticals Inc
- Catalent Inc
- Shanghai Miracogen Inc
- Antikor Biopharma Ltd
- Telix Pharmaceuticals Ltd
- OBI Pharma Inc
- Bayer AG
- Debiopharm International SA
- Tagworks Pharmaceuticals BV
- Eli Lilly and Co
- Adcentrx Therapeutics Inc
- Genentech USA Inc.
For more information about this report visit https://www.researchandmarkets.com/r/qwpibm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
